The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.

M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.

The potential impact of the BIOSECURE Act continues to spread as the Biden administration increases its focus on China. But with BIO's top lobbyist and the top House sponsor of the legislation now headed out the door, the future of the bill remains uncertain.

Apotex has taken a major step to bolster its innovative interests with the acquisition of fellow Canadian firm and specialty branded player Searchlight Pharma.